Spironolactone for heart failure with preserved ejection fraction - The New England Journal of Medicine - 2014
Brief Summary:
Among patients with heart failure with preserved ejection fraction, spironolactone does not reduce the composite endpoint of CV mortality, aborted cardiac arrest, or HF hospitalizations when compared to placebo. However, it is associated with small reduction in HF hospitalizations.Reference: http://www.ncbi.nlm.nih.gov/pubmed/24716680
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you